BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo

BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo

Abstract Background Multidrug resistance (MDR) limits successful cancer chemotherapy. P-glycoprotein (P-gp), BCRP and MRP1 are the key triggers of MDR. Unfortunately, no MDR modulator was approved by FDA to date. Here, we will investigate the effect of BI-2865, a pan-KRAS inhibitor, on reversing MDR...

Full description

Bibliographic Details
Main Authors: Qihong Yang, Kenneth Kin Wah To, Guilin Hu, Kai Fu, Chuan Yang, Shuangli Zhu, Can Pan, Fang Wang, Kewang Luo, Liwu Fu
Format: Article
Language:English
Published: BMC 2024-06-01
Series:Cell Communication and Signaling
Subjects:
KRAS inhibitor
BI-2865
Multidrug resistance
ABC transporters
ABCB1/P-gp
Chemotherapeutic agent
Online Access:https://doi.org/10.1186/s12964-024-01698-4

Internet

https://doi.org/10.1186/s12964-024-01698-4

Similar Items